Table 5

The diagnostic accuracies of the three new combinations and the standard combination in distinguishing between NPC cases and controls

CombinationNew cut-off values†Sensitivity (%)Specificity (%)AUC
(95% CI)
p Value§
Early stage
(95% CI)
Advanced stage
(95% CI)‡
Total
(95% CI)
Control
(95% CI)
BB+EBNA1-IgA0.25897.0
(85.0 to 100)
92.8
(89.2 to 96.4)
93.5
(90.1 to 96.9)
95.0
(92.0 to 98.0)
0.977
(0.963 to 0.991)
<0.001
HA+EBNA1-IgA0.37997.0
(85.0 to 100)
86.2
(81.5 to 91.0)
88.0
(83.5 to 92.5)
94.0
(90.7 to 97.3)
0.961
(0.943 to 0.979)
<0.001
KSB+EBNA1-IgA0.19193.9
(80 to 100)
94.6
(91.5 to 97.7)
94.5
(91.3 to 97.7)
87.0
(82.3 to 91.7)*
0.964
(0.947 to 0.981)
<0.001
Standard combination0.99897.0
(85 to 100)
88.6
(84.2 to 93.0)
90.0
(85.8 to 94.2)
95.5
(92.6 to 98.4)
0.970
(0.956 to 0.985)
  • †New cut-off value for NPC diagnosis was defined as the value with the largest Youden Index chosen from each ROC.

  • ‡Differences in the sensitivity of early-stage and advanced-stage NPC were compared by Pearson’s χ2 tests. p<0.05 was considered as statistically significant.

  • §p Values were estimated by non-inferiority tests based on the bootstrap approach for AUC between new combinations and the standard combination. p<0.05 was considered as statistically significant, whereas p>0.05 was consider to be inferior to the standard kit.